Vitamin D-binding protein, circulating vitamin D and risk of renal cell carcinoma

International Journal of Cancer

Volumn 134, Issue 11, 2014, Pages 2699-2706

  Mondul, Alison M ^a   Weinstein, Stephanie J ^a   Moy, Kristin A ^a   Männistö, Satu ^b   Albanes, Demetrius ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

25 hydroxyvitamin D; prospective studies; renal cell carcinoma; vitamin D binding protein

Indexed keywords

25 HYDROXYVITAMIN D; VITAMIN D BINDING PROTEIN;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; VITAMIN BLOOD LEVEL;

25-HYDROXYVITAMIN D; PROSPECTIVE STUDIES; RENAL CELL CARCINOMA; VITAMIN D-BINDING PROTEIN;

AGED; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; VITAMIN D; VITAMIN D-BINDING PROTEIN;

EID: 84896388854     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28596     Document Type: Article

References (24)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Cho E, Adami HO, Lindblad P,. Epidemiology of renal cell cancer. Hematol Oncol Clin North Am 2011; 25: 651-65.
3. Lambert JR, Eddy VJ, Young CD, et al. A vitamin D receptor-alkylating derivative of 1alpha,25-dihydroxyvitamin D3 inhibits growth of human kidney cancer cells and suppresses tumor growth. Cancer Prev Res 2010; 3: 1596-607.
4. Joh HK, Giovannucci EL, Bertrand KA, et al. Predicted plasma 25-hydroxyvitamin d and risk of renal cell cancer. J Natl Cancer Inst 2013; 105: 726-32.
5. Gallicchio L, Moore LE, Stevens VL, et al. Circulating 25-hydroxyvitamin D and risk of kidney cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol 2010; 172: 47-57.
6. Mondul AM, Weinstein SJ, Virtamo J, et al. Influence of vitamin D binding protein on the association between circulating vitamin D and risk of bladder cancer. Br J Cancer 2012; 107: 1589-94.
7. Weinstein SJ, Mondul AM, Kopp W, et al. Circulating 25-hydroxyvitamin D, vitamin D-binding protein and risk of prostate cancer. Int J Cancer 2013; 132: 2940-7.
8. Weinstein SJ, Stolzenberg-Solomon RZ, Kopp W, et al. Impact of circulating vitamin D binding protein levels on the association between 25-hydroxyvitamin d and pancreatic cancer risk: a nested case-control study. Cancer Res 2012; 72: 1190-8.
9. Bikle DD, Gee E,. Free, and not total, 1,25-dihydroxyvitamin D regulates 25-hydroxyvitamin D metabolism by keratinocytes. Endocrinology 1989; 124: 649-54.
10. Pike JW, Feldman D, Glorieux FH,. Vitamin D. San Diego, CA: Academic Press, 1997.
11. Speeckaert M, Huang G, Delanghe JR, et al. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta 2006; 372: 33-42.
12. The ATBC Cancer Prevention Study Group. The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. Ann Epidemiol 1994; 4: 1-10.
13. Gallicchio L, Helzlsouer KJ, Chow WH, et al. Circulating 25-hydroxyvitamin D and the risk of rarer cancers: design and methods of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol 2010; 172: 10-20.
14. Korhonen P, Malila N, Pukkala E, et al. The Finnish Cancer Registry as follow-up source of a large trial cohort-accuracy and delay. Acta Oncol 2002; 41: 381-8.
15. Ersfeld DL, Rao DS, Body JJ, et al. Analytical and clinical validation of the 25 OH vitamin D assay for the LIAISON automated analyzer. Clin Biochem 2004; 37: 867-74.
16. (NIST) NIoSaT. Certificate of analysis, standard reference matiral 972 vitamin D in human serum, vol. 2009. Gaithersburg, MD: National Institute of Standards and Techology, 2009.
17. Al-oanzi ZH, Tuck SP, Raj N, et al. Assessment of vitamin D status in male osteoporosis. Clin Chem 2006; 52: 248-54.
18. Bouillon R, Van Assche FA, Van Baelen H, et al. Influence of the vitamin D-binding protein on the serum concentration of 1,25-dihydroxyvitamin D3. Significance of the free 1,25-dihydroxyvitamin D3 concentration. J Clin Invest 1981; 67: 589-96.
19. Andreassen TK,. The role of plasma-binding proteins in the cellular uptake of lipophilic vitamins and steroids. Horm Metab Res 2006; 38: 279-90.
20. Willnow TE, Nykjaer A,. Cellular uptake of steroid carrier proteins - mechanisms and implications. Mol Cell Endocrinol 2010; 316: 93-102.
21. Albanes D, Mondul AM, Yu K, et al. Serum 25-hydroxy vitamin D and prostate cancer risk in a large nested case-control study. Cancer Epidemiol Biomarkers Prev 2011; 20: 1850-60.
22. Stolzenberg-Solomon RZ, Hayes RB, Horst RL, et al. Serum vitamin D and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian screening trial. Cancer Res 2009; 69: 1439-47.
23. Stolzenberg-Solomon RZ, Jacobs EJ, Arslan AA, et al. Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol 2010; 172: 81-93.
24. Malik S, Fu L, Juras DJ, et al. Common variants of the vitamin D binding protein gene and adverse health outcomes. Crit Rev Clin Lab Sci 2013; 50: 1-22.